ZBTB7A specifically binds to cis‐acting elements in the promoter region of genes through a DNA‐binding domain and synergistically represses the transcription of target genes through the recruitment of inhibitory complexes (NCoR and HDAC).[40, 41] While Liu et al.[14] reported that reduced ZBTB7A expression in colon cancer patients was positively correlated with the upregulation of the glycolytic genes Glut3, Pfkp, and Pkm and poor patient survival. Here, PFKP is linked to malignant colon neoplasm.